Carlsmed Inc (CARL) Stock Forecast & Price Target

Carlsmed is a commercial-stage medical technology company with a promising niche in AI-enabled personalized solutions for spine surgery, driven by the successful launch of its aprevo technology platform. With a robust revenue and EPS performance in the latest quarter, the company increased its FY26 revenue guidance to $72M-$77M, while also seeing early contributions and a growing customer base for its newly launched aprevo Cervical product. Furthermore, the upcoming implementation of a new proposed reimbursement policy is expected to drive broader hospital adoption of Carlsmed's products. Based on a strong track record and potential for upside, financial analysts recommend a Buy rating for the stock with a target price of $23.

Carlsmed is a single operating segment company that relies on selling its Aprevo technology platform to hospitals and ambulatory surgical centers, but its growth projections seem aggressive, as it assumes a ~43% CAGR through FY27, which could be challenging to achieve. Additionally, while the company has seen an increase in surgeon utilization, there is limited variability within the customer base, suggesting potential saturation in the market. This, coupled with relatively conservative estimates for Lumber utilization, casts doubt on the company's ability to sustain high growth and reach profitability in the near future.